Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis

References

• NCI. General Information About Breast Cancer. 2023. [cited 2023 Feb 9]. Available from: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq#section/_1.
   Google Scholar
• IARC. Cancer Today. 2020. [cited 2023 Feb 9]. Available from: https://gco.iarc.fr/today/home.
   Google Scholar
• Toyoda Y, Tabuchi T, Nakayama T, et al. Past trends and future estimation of annual breast cancer incidence in Osaka, Japan. Asian Pac J Cancer Prev. 2016;17:2847–2852.
   PubMedGoogle Scholar
• Kawamura T, Sobue T. Comparison of breast cancer mortality in five countries: France, Italy, Japan, the UK and the USA from the WHO mortality database (1960–2000). Jpn J Clin Oncol. 2005;35(12):758–759. doi: 10.1093/jjco/hyi201.
   PubMedGoogle Scholar
• Yoshimura A, Ito H, Nishino Y, et al. Recent improvement in the long-term survival of breast cancer patients by age and stage in Japan. J Epidemiol. 2018;28(10):420–427. doi: 10.2188/jea.JE20170103.
   PubMed Web of Science ®Google Scholar
• Japanese Breast Cancer Society. The Japanese breast cancer society clinical practice guidelines for breast cancer 2022 treatment. Tokyo: Kanehara Shuppan; 2022.
   Google Scholar
• Shimoi T, Nagai SE, Yoshinami T, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27(3):322–331. doi: 10.1007/s12282-020-01085-0.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. doi: 10.6004/jnccn.2022.0030.
   PubMed Web of Science ®Google Scholar
• Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010;107(6):85–91. doi: 10.3238/arztebl.2010.0085.
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3(S3):20–29. doi: 10.1634/theoncologist.10-90003-20.
   PubMedGoogle Scholar
• Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment—a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800–809. doi: 10.1158/1055-9965.EPI-11-1089.
   PubMed Web of Science ®Google Scholar
• Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296–311. doi: 10.1038/s41571-018-0145-5.
   PubMed Web of Science ®Google Scholar
• Győrffy B, Hatzis C, Sanft T, et al. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17(1):11. doi: 10.1186/s13058-015-0514-2.
   PubMedGoogle Scholar
• Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308–2324. doi: 10.1007/s00268-010-0683-1.
   PubMed Web of Science ®Google Scholar
• Agarwal G, Pradeep PV, Aggarwal V, et al. Spectrum of breast cancer in Asian women. World J Surg. 2007;31(5):1031–1040. doi: 10.1007/s00268-005-0585-9.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Nakayama T, Nakamura S, et al. Baseline characteristics of patients from Asia enrolled in monarchE, evaluating abemaciclib in high risk early breast cancer. Ann Oncol. 2020;31(S6):S1241. doi: 10.1016/j.annonc.2020.10.022.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34. doi: 10.1016/j.jclinepi.2009.06.006.
   PubMed Web of Science ®Google Scholar
• Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–286. doi: 10.7326/0003-4819-158-4-201302190-00009.
   PubMed Web of Science ®Google Scholar
• Sidik K, Jonkman JN. A simple confidence interval for meta-analysis. Stat Med. 2002;21(21):3153–3159. doi: 10.1002/sim.1262.
   PubMed Web of Science ®Google Scholar
• Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20(24):3875–3889. doi: 10.1002/sim.1009.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1(2):112–125. doi: 10.1002/jrsm.11.
   PubMed Web of Science ®Google Scholar
• Shibuta K, Ueo H, Furusawa H, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer. 2011;18(4):292–298. doi: 10.1007/s12282-010-0209-6.
   PubMed Web of Science ®Google Scholar
• Tokiniwa H, Horiguchi J, Takata D, et al. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer. 2012;19(4):309–314. doi: 10.1007/s12282-011-0291-4.
   PubMed Web of Science ®Google Scholar
• Hisamatsu Y, Tokunaga E, Yamashita N, et al. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012;19(4):1145–1152. doi: 10.1245/s10434-011-2094-4.
   PubMed Web of Science ®Google Scholar
• Ishitobi M, Ohsumi S, Inaji H, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson prognostic index. Cancer. 2012;118(18):4385–4393. doi: 10.1002/cncr.27377.
   PubMed Web of Science ®Google Scholar
• Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–352. doi: 10.1016/S1470-2045(11)70373-4.
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Okada S, Yamashita N, et al. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Breast Cancer. 2012;19(2):161–169. doi: 10.1007/s12282-010-0232-7.
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Nishimura R, Osako T, et al. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer. Anticancer Res. 2013;33:3891–3897.
   PubMed Web of Science ®Google Scholar
• Satoh K, Tanaka M, Yano A, et al. Treatment when prognostic factors do not match St. Gallen recommendations: profiling of prognostic factors among HR(+) and HER2(–) breast cancer patients. World J Surg. 2013;37(3):516–524. doi: 10.1007/s00268-012-1881-9.
   PubMed Web of Science ®Google Scholar
• Kurebayashi J, Kanomata N, Shimo T, et al. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer. 2014;21(2):214–222. doi: 10.1007/s12282-012-0380-z.
   PubMed Web of Science ®Google Scholar
• Niikura N, Masuda S, Kumaki N, et al. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer. 2014;14(5):323–329.e3. doi: 10.1016/j.clbc.2013.12.013.
   PubMed Web of Science ®Google Scholar
• Nishimiya H, Kosaka Y, Yamashita K, et al. Prognostic significance of Ki-67 in chemotherapy-naïve breast cancer patients with 10-year follow-up. Anticancer Res. 2014;34:259–268.
   PubMed Web of Science ®Google Scholar
• Hisamatsu Y, Tokunaga E, Yamashita N, et al. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. Breast Cancer. 2015;22(5):520–528. doi: 10.1007/s12282-013-0515-x.
   PubMed Web of Science ®Google Scholar
• Honma N, Horii R, Ito Y, et al. Differences in clinical importance of bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer. 2015;15(1):698. doi: 10.1186/s12885-015-1686-y.
   PubMedGoogle Scholar
• Kawase M, Toyama T, Takahashi S, et al. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. 2015;22(3):308–316. doi: 10.1007/s12282-013-0482-2.
   PubMed Web of Science ®Google Scholar
• Nishimukai A, Yagi T, Yanai A, et al. High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer. Clin Breast Cancer. 2015;15(3):204–211. doi: 10.1016/j.clbc.2014.12.007.
   PubMed Web of Science ®Google Scholar
• Ono M, Tsuda H, Yunokawa M, et al. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. Breast Cancer. 2015;22(2):141–152. doi: 10.1007/s12282-013-0464-4.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Nishimukai A, Ozawa H, et al. Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes. Breast. 2016;30:5–12. doi: 10.1016/j.breast.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Kawai M, Tomotaki A, Miyata H, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese national clinical database–breast cancer registry. Cancer Med. 2016;5(6):1328–1340. doi: 10.1002/cam4.678.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Shien T, Ogiya A, et al. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. Breast Cancer Res. 2016;18(1):73. doi: 10.1186/s13058-016-0731-3.
   PubMedGoogle Scholar
• Okuma HS, Koizumi F, Hirakawa A, et al. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. Br J Cancer. 2016;115(4):411–419. doi: 10.1038/bjc.2016.184.
   PubMed Web of Science ®Google Scholar
• Sato K, Miyashita M, Ishida T, et al. Prognostic significance of the progesterone receptor status in Ki67-high and low luminal B-like HER2-negative breast cancers. Breast Cancer. 2016;23(2):310–317. doi: 10.1007/s12282-014-0575-6.
   PubMed Web of Science ®Google Scholar
• Kurozumi S, Matsumoto H, Hayashi Y, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer. 2017;17(1):354. doi: 10.1186/s12885-017-3331-4.
   PubMedGoogle Scholar
• Ono M, Tsuda H, Yoshida M, et al. Prognostic significance of progesterone receptor expression in estrogen-receptor positive, HER2-negative, node-negative invasive breast cancer with a low Ki-67 labeling index. Clin Breast Cancer. 2017;17(1):41–47. doi: 10.1016/j.clbc.2016.06.012.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Takahashi Y, Matsuda N, et al. The prognostic effect of changes in tumor stage and nodal status after neoadjuvant chemotherapy in each primary breast cancer subtype. Clin Breast Cancer. 2018;18(2):e219–29–e229. doi: 10.1016/j.clbc.2017.09.013.
   Web of Science ®Google Scholar
• Imamura M, Morimoto T, Nomura T, et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018;16(1):26. doi: 10.1186/s12957-018-1325-6.
   PubMedGoogle Scholar
• Kurozumi S, Matsumoto H, Inoue K, et al. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS One. 2018;13(8):e0201846. doi: 10.1371/journal.pone.0201846.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Mukai H, Tokudome Y, et al. Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors. Jpn J Clin Oncol. 2018;48(3):248–254. doi: 10.1093/jjco/hyy001.
   PubMed Web of Science ®Google Scholar
• Arima N, Nishimura R, Osako T, et al. Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors. Oncol Lett. 2019;17:616–622.
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Watanabe T, Hida AI, et al. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Breast Cancer. 2019;26(6):738–747. doi: 10.1007/s12282-019-00977-0.
   PubMed Web of Science ®Google Scholar
• Naoi Y, Saito Y, Kishi K, et al. Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer. Oncol Rep. 2019;42(6):2680–2685. doi: 10.3892/or.2019.7358.
   PubMed Web of Science ®Google Scholar
• Ohara AM, Naoi Y, Shimazu K, et al. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. Breast Cancer Res Treat. 2019;173(3):533–543. doi: 10.1007/s10549-018-5020-7.
   PubMed Web of Science ®Google Scholar
• Takuwa H, Tsuji W, Yotsumoto F, et al. Prevention of locoregional recurrence and distant metastasis in japanese breast cancer patients using Japanese standard postoperative radiation fields: experience at a single institution. Cancer Rep. 2019;2:e1191.
   Google Scholar
• Horimoto Y, Sasahara N, Sasaki R, et al. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast Cancer Res Treat. 2020;183(1):41–48. doi: 10.1007/s10549-020-05751-x.
   PubMed Web of Science ®Google Scholar
• Ishiguro H, Masuda N, Sato N, et al. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat. 2020;180(3):715–724. doi: 10.1007/s10549-020-05590-w.
   PubMed Web of Science ®Google Scholar
• Sugano T, Yoshida M, Masuda M, et al. Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. Br J Cancer. 2020;122(12):1811–1817. doi: 10.1038/s41416-020-0821-y.
   PubMed Web of Science ®Google Scholar
• Fujihara M, Yamasaki R, Ito M, et al. Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients. BMC Womens Health. 2021;21:147.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Fukui T, Nomizu T, et al. TP53 signature diagnostic system using multiplex reverse transcription–polymerase chain reaction system enables prediction of prognosis of breast cancer patients. Breast Cancer. 2021;28(6):1225–1234. doi: 10.1007/s12282-021-01250-z.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Ohno T, Kadonaga T, et al. Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 − negative subtype. Breast Cancer. 2021;28(4):822–828. doi: 10.1007/s12282-021-01217-0.
   PubMed Web of Science ®Google Scholar
• Toi M, Imoto S, Ishida T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(1):74–84. doi: 10.1016/S1470-2045(20)30534-9.
   PubMed Web of Science ®Google Scholar
• Kurozumi S, Kaira K, Matsumoto H, et al. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Sci Rep. 2022;12(1):2742. doi: 10.1038/s41598-022-06615-8.
   PubMed Web of Science ®Google Scholar
• Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, et al. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer. 2022;29(2):368–376. doi: 10.1007/s12282-021-01319-9.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Chishima T, Shibata Y, et al. Stratification of prognosis by biological features following neoadjuvant chemotherapy in luminal breast cancer. In Vivo. 2022;36(2):859–864. doi: 10.21873/invivo.12774.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–1235. doi: 10.1016/j.annonc.2021.06.023.
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi: 10.1200/JCO.20.02514.
   PubMed Web of Science ®Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. doi: 10.1200/JCO.19.02309.
   PubMed Web of Science ®Google Scholar
• Beadle BM, Woodward WA, Buchholz TA. The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol. 2011;21(1):26–34. doi: 10.1016/j.semradonc.2010.09.001.
   PubMed Web of Science ®Google Scholar